LIR Life Sciences Corp. SKNY
CNSX
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 30.55% | 34.62% | -1,005.17% | -38.43% | 33.98% |
| Total Depreciation and Amortization | -- | -10.00% | 0.00% | 25.00% | -- |
| Total Amortization of Deferred Charges | -- | -201.14% | -- | -- | -- |
| Total Other Non-Cash Items | -70.48% | 99.86% | 489,200.00% | -200.00% | -- |
| Change in Net Operating Assets | 664.46% | 91.90% | -319.06% | 106.67% | -32.17% |
| Cash from Operations | 7.15% | 73.08% | -28,225.00% | 88.60% | 38.64% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -93.07% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 100.00% | -- |
| Cash from Investing | -- | -93.07% | -- | 100.00% | -- |
| Total Debt Issued | -- | -- | -100.00% | -85.71% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -100.00% | 2,931.37% | 118.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -19.80% | -120.11% | -113.97% | 993.03% | 55.50% |